Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study

被引：24

作者：

Visacri, Marilia Berlofa ^{[1
]}

Pincinato, Eder de Carvalho ^{[2
]}

Ferrari, Graziele Baldan ^{[1
]}

Franca Quintanilha, Julia Coelho ^{[1
]}

Mazzola, Priscila Gava ^{[3
]}

Passos Lima, Carmen Silvia ^{[1
]}

Moriel, Patricia ^{[3
]}

机构：

[1] Univ Campinas UNICAMP, Sch Med Sci FCM, 126 Cidade Univ Zeferino Vaz, BR-13083887 Campinas, SP, Brazil

[2] Univ Prebiteriana Mackenzie, Sci Ctr, Dept Biol & Hlth, Rua Consolacao 896, BR-01302907 Sao Paulo, SP, Brazil

[3] Univ Campinas UNICAMP, Fac Pharmaceut Sci FCF, 200 Cidade Univ Zeferino Vaz Barao Geraldo, BR-13083871 Campinas, SP, Brazil

来源：

DARU-JOURNAL OF PHARMACEUTICAL SCIENCES | 2017年 / 25卷

基金：

巴西圣保罗研究基金会;

关键词：

Adverse drug reaction; Excretion; Urine; Cisplatin; Chemotherapy; Head and neck cancer; HIGH-DOSE CISPLATIN; RADIATION-THERAPY; BIOLOGICAL-FLUIDS; PLATINUM; CIS-DIAMMINEDICHLOROPLATINUM(II); PHARMACOKINETICS; CARCINOMA; CONCURRENT; PROFILES; TOXICITY;

D O I：

10.1186/s40199-017-0178-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Cisplatin is a high-potency anticancer agent; however, it causes significant adverse drug reactions (ADRs). Potential pharmacokinetic markers must be studied to predict or prevent cisplatin-induced ADRs and achieve better prognosis. This study was designed to investigate the relationship between ADRs and kinetics of cisplatin excretion in the urine of patients undergoing high-dose cisplatin chemotherapy and radiotherapy for head and neck cancer. Methods: Outpatients with head and neck cancer received a first cycle of high-dose cisplatin chemotherapy (80-100 mg/m(2)) concurrent to radiotherapy. ADRs (haematological, renal, and gastrointestinal reactions) were classified based on severity by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, version 4, grade 0-4). The kinetics of cisplatin excretion in urine was evaluated by high-performance liquid chromatography over three time periods: 0-12, 12-24, and 24-48 h after the administration of cisplatin. Spearman Correlation test and regression analysis were performed to assess the relationship between ADRs and cisplatin excretion in the urine. Results: In total, 59 patients with a mean age of 55.6 +/- 9.4 years were analysed; most patients were male (86.4%), white (79.7%), and with pharyngeal tumours in advanced stages (66.1%). The most frequently observed ADRs were anaemia (81.4%), lymphopenia (78%), and nausea (64.4%); mostly grades 1 and 2 of toxicity. The mean cisplatin excretion was 70.3 +/- 64.4, 7.3 +/- 6.3, and 5 +/- 4 mu g/mg creatinine at 0-12, 12-24, and 24-48 h, respectively. Statistical analysis showed that the amount of cisplatin excreted did not influence the severity of ADRs. Conclusions: The most frequent ADRs were anaemia, lymphopenia, and nausea. Grades 1 and 2 were the severities for most ADRs. The period over which the highest cisplatin excretion observed was 0-12 h after chemotherapy, and cisplatin excretion could not predict toxicity.

引用

页数：9

共 43 条

[1] Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].